Factor Report

Data as of market close on 11/27/2020.

Validea's factor report analyzes any stock using the major investing factors, including value, quality, momentum, and low volatility.
View User Guide    Video Tutorial

NGM BIOPHARMACEUTICALS INC (NGM)

View Guru Analysis
Latest Close: $23.85 Market Cap ($ mil): $1,646 Sector: Healthcare Industry: Biotechnology & Drugs 52 Week High: $24.54 52 Week Low: $9.24 Relative Strength: 80 Twelve Minus One Return: 5.9% Standard Deviation: 63.3%
PE Ratio: N/A Price/Sales: 16.7 Price/Book: 5.9 Price/Cash Flow: N/A EV/EBITDA: N/A Yield: N/A Shareholder Yield: 10.46% F Score: 3 G Score: 7
Return on Equity: -29.4% Return on Assets: -25.2% Return on Tangible Capital: -32.4% Return on Invested Capital: N/A WACC: N/A Debt/Equity: 0.00 LT EPS Growth: N/A LT Sales Growth: -9.0% Beta: N/A
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The Company's product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.

Factor Profile

NGM's exposure to the major factors (100 is highest).

Comparable Stocks

Stocks with the closest factor profiles to NGM.

(click ticker to access stock report and name to view guru analysis)

Ticker Ticker
AXNX EDIT
CLLS YMAB
PHAT APRE
Performance Disclaimer: Returns presented on Validea.com are model returns and do not represent actual trading. As a result, they do not incorporate any commissions or other trading costs or fees. Model portfolios with inception dates on or after 12/30/2005 include a combination of back tested and live model returns. The back-tested performance results shown are hypothetical and are not the result of real-time management of actual accounts. The back-testing of performance differs from actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Back-tested returns are presented to provide general information regarding how the underlying strategy behind the portfolio performed in our historical testing. A back-tested strategy has the benefit of hindsight and the results do not reflect the impact that material economic or market factors may have had on advisor's decision-making if actual client assets were being managed using this approach.

Optimal portfolios presented on Validea.com represent the rebalancing period that has led to the best historical performance for each of our equity models. Each optimal portfolio was determined after the fact with performance information that was not available at portfolio inception. As a result, an investor could not have invested in the optimal portfolio since its inception. Optimal portfolios are presented to allow investors to quickly determine the portfolio size and rebalancing period that has performed best for each of our models in our historical testing.

Both the model portfolio and benchmark returns presented for all equity portfolios on Validea.com are not inclusive of dividends. Returns for our ETF portfolios and trend following system, and the benchmarks they are compared to, are inclusive of dividends. The S&P 500 is presented as a benchmark because it is the most widely followed benchmark of the overall US market and is most often used by investors for return comparison purposes. As with any investment strategy, there is potential for profit as well as the possibility of loss and investors may incur a loss despite a past history of gains. Past performance does not guarantee future results. Results will vary with economic and market conditions.